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ABSTRACT 
Objectives: To assess the prognostic role of proviral DNA in 
peripheral blood mononuclear cells (PBMC) of patients with 
undetectable viremia over long-term highly active antiretroviral 
therapy (HAART) 
kfethods: Eighty-two human immunodeficiency virus (HIV-1 - 
infected patients, free of acquired immunodeficiency syndrome 
(AIDS), received zidovudine plus lamivudine plus indinavir. Lev- 
els of plasma HIV-RNA, and PBMC proviral DNA and RNA 
unspliced (US) transcripts were evaluated by using competitive 
polymerase chain reaction (cPCR) assays, every 3 months over 
1 year. 
Results: Among patients with undetectable viremia at baseline, 
13 of 18 with CD4 cell count 350/mm3 or less and 12 of 16 
with CD4 between 351 and 700/mm3, constantly maintained 
undetectable RNA levels; in these patients, a mean proviral 
DNA decrease of 0.67 i- 0.7 and 1.03 -C 0.53 log (P < 0.001) 
respectively, a significant decrease of RNA-US transcripts 
(P < O.OOl), and significant correlations between decreases 
of proviral DNA and RNA-US transcripts (P = 0.008 and 
P < 0.001, respectively) were observed. 
Conc/usions: Proviral DNA quantitation permits the continued 
monitoring of HAART in patients with undetectable viremia. 
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Several controlled clinical trials have provided evidence 
that plasma human immunodeficiency virus (HIWRNA 
levels are strongly correlated with disease progression, 
CD4 Tcell count, and response to antiretroviral therapy.‘-* 
In a recent follow-up report, the Multicenter AIDS Cohort 
Study (MACS) group demonstrated improved pre- 
dictability of outcome when viral load and CD4 count 
were used togethet5 The viral load monitoring, using sev- 
eral plasma HIV-RNA assays is incorporated into routine 
clinical practice and provides clinicians with the tools to 
start therapy as well as to monitor and adjust antiretro- 
viral regimens on the basis of changes in viral load over 
time. 
Emerging data from ongoing clinical trials indicate 
that in the majority of patients treated with highly active 
antiretroviral therapy (HAART), HIV-RNA in plasma 
reached undetectable levels in 24 weeks6,’ and the virus 
cannot be recovered from peripheral blood mononuclear 
cells (PBMC) or lymphoid tissue samples by standard 
co-culture techniques.*s9 
However, several groups have reported that viral DNA 
remains detectable in PBMCs as well as in lymphoid tis- 
sues, and the virus can be isolated from PBMCs by using 
enhanced co-culture conditions even after more than one 
year of HAART. ‘OJ~ These studies suggest that the virus 
could be derived from long-living cells that have been 
infected before the initiation of therapy and, despite pro 
longed suppression of plasma viremia, they represent an 
important viral reservoir that seems not to be modified 
during HAART. 
Although these cells are present in low amounts 
(about 1 X lo5 to 1 X lo6 cells in the entire body), some 
of them harbor replication-competent provirusl* Given 
this, residual viral burden in PBMCs should be evaluated, 
as an indicator for monitoring of HAART, and further diag- 
nostic tools are required for continued monitoring of 
patients whose plasma viremia has been reduced to un- 
detectable levels by aggressive antiretroviral therapies. In 
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the past few years, much effort has been placed in the 
development of polymerase chain reaction (PCR)-based 
methods for the clinical applicability of provit-al DNA quan- 
titation in PBMCs.‘“-16 In addition, the quantitative analysis 
of HIV-1 viremia, viral gag transcripts, and proviral DNA 
sequences in PBMCs by competitive PCR (cPCR) and 
reverse transcription PCR (cRTPCR) has been extensively 
used to examine the level of HIV-1 activity in infected 
patients at different stages of the disease and during anti- 
retroviral therapies, thus providing a more complete eval- 
uation of the molecular profile of HIV-1 infection.1T-2n 
In this study, sequential blood samples were obtained 
from 82 infected patients during 1 year of HAART; 
changes in proviral DNA levels were compared with 
those of unspliced (US) RNA transcripts in PBMCs and 
RNA in plasma, according to immunologic status. 
The goal of this study was to evaluate the prognos- 
tic role of proviral DNA levels in PBMCs in aggressively 
treated patients with undetectable plasma viremia. 
MATERIALS AND METHODS 
Study Subjects 
Eighty-two HIV-l seropositive patients, attending the 
Department of Infectious and Tropical Diseases of the 
University of Pavia were enrolled in the study All patients 
were currently taking antiretroviral treatments, including 
zidovudine plus didanosine or zidovudine plus lamivu- 
dine from 3 months to 1 year and completed a screen- 
ing visit within 1 month of the start of the study. Patients 
were selected who met each of the following criteria: 
(1) plasma HIV-RNA levels 5000 copies/ml or less, (2) 
CD4 cell count from 200 to 700/p,m”, and (3) strict adher- 
ence to current antiretroviral treatment. 
Patients were excluded if they had received any HIV- 
protease inhibitor, if they required maintenance therapy 
for an opportunistic infection, or if they had received 
investigational or immunomodulatory drugs within 
30 days before entry into the study. Exclusion criteria 
also included neutrophil count less than 1.0 X 109/L; 
hemoglobin levels more than three times the lower limit 
of the normal range; alkaline phosphatase and serum cre- 
atinine levels more than 2.5 or 1.5 times, respectively, of 
the upper limit of normal range, and Karnofsky score 
below 80 points. Patients were classified according to the 
Centers for Disease Control and Prevention (CDC) clas- 
sification system. 
Patients were given a combination of zidovudine 
(ZVD, 300 mg twice daily), lamivudine (3-TC, 150 mg 
twice daily), and indinavir (IDV 800 mg three times daily). 
The patients were followed before starting the treatment 
and every 3 months for 1 year of tripIe drug therapy, 
with a clinical assessment and routine laboratory moni- 
toring: CD4+ T-cell counts were determined twice at base- 
line and at each time point, and concentrations of HIV-l 
RNA in plasma, proviral DNA, and US-RNA transcripts in 
PBMCs were determined twice at baseline and once at 
each time point. 
Preparation of Clinical Samples 
and Nucleic Acid Purification 
Ethylenediaminetetraacetic acid (EDTA)-treated periph- 
eral blood was centrifuged at 600 g for 10 minutes. Plasma 
was recovered, and platelets and cell debris were 
removed at 1800 g for 10 minutes. Clarified plasma was 
aliquoted and stored at -80°C until RNA extraction. Blood 
cells were resuspended in Hank’s balanced salt solution 
(HBSS; Gibco Life Tecnologies, Paisley, Scotland, UK) and 
centrifuged over a Ficoll density gradient (Lymphoprep, 
Nycomed Pharma AS, Oslo, Norway): PBMCs were recov- 
ered and washed three times with HBSS. For DNA prepa- 
ration, PBMCs were resuspended in lysis buffer (10 
mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCI, 0.5% Tween 
20,0.5% NP 40,1.5 mmol/L MgCl,) at the concentration 
of lO’/mL and treated with proteinase K (120 kg/mL) 
for 4 hours at 56°C. The proteinase was inactivated by 
heating at 95°C for 10 minutes, and the lysate was stored 
at -20°C until PCR analysis. RNA was extracted from 
PBMCs and plasma samples using the guanidinium thio- 
cyanate method as previously described.21 RNA samples 
were then used immediately as RT-PCR template or stored 
at -80°C for subsequent analysis. 
Quantitative Analysis of HIV-DNA and HIV-RNA 
The following substrates were analyzed using quantita- 
tive cPCR and cRTPCR: (1) genomic RNA from plasma, 
(2) US-RNA transcripts from PBMCs, and (3) proviral DNA 
from PBMCs. Quantitation of HIV-DNA and HIV-RNA, 
using cPCR and CRT-PCR, was performed as previously 
described in detail. l7 
Briefly, the same RNA (5 pL, equivalent to 100 PL of 
plasma or lo5 PBMCs) or DNA (5 ~J,L, equivalent to lo5 
PBMCs) sample was reverse transcribed or amplified in 
four reaction tubes containing 5 FL of competitor RNA or 
competitor DNA at increasing copy number (10-1250). 
Each RNA sample was reverse transcribed for 30 minutes 
at 42°C in 2O+L final volume containing 1 X PCR reac- 
tion buffer (50 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 8.3, 
1.5 mmol/l MgCl,), 100 units of Maloney murine leukemia 
virus reverse transcriptase (RT, Gibco Life Technologies), 
50 pmol of the SK39 primer, 0.2 mM of each deoxynu- 
cleoside triphosphate (dNTPs), 2 units of RNasin and 5 FL 
of competitor RNA. The cDNA was then heated in the 
same mixture for 5 minutes at 95°C. Each cDNA sample 
was amplified in a 5O+L mixture containing, at a final 
concentration, 1 X PCR reaction buffer, 0.2 n&l of each 
dNTP 50 pmol of each SK 38 and SK 39 primers and 1.5 
units of Taq polymerase (Pet-kin-Elmer Cetus, Emeryville, 
California, USA). DNA samples were amplified in the same 
mixture containing 5 FL of competitor DNA. The PCR 
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profile (94’C, 20 s; 60”~ 30 s; 72°C 30 s) was repeated 
for 50 cycles. At the end of the last cycle the DNA was 
further extended at 72°C for 10 minutes. The amplifica- 
tion products were run on a 10% polyacrylamide gel and 
ethidium bromide stained. The peak areas of DNA band 
fluorescence emission were analyzed with a video den- 
sitometer (Gel Dot 1000, Bio Rad Laboratories, Richmond, 
CA, USA) as previously described. To ensure that suffi- 
cient DNA was present in the PBMC preparations and 
that inhibitors were absent from the reaction mixtures, 
the P-globin gene was amplified in the same DNA sam- 
ples.22 Parallel reactions were carried out in the absence 
of the reverse transcription step as a control for RNA 
specificity. 
In these experimental conditions, the lower limit of 
detection of the assay was 50 RNA copies/ml of plasma 
and 2 DNA or RNA copies/lo’ PBMCs. Quantitative data 
of cellular parameters were then normalized to the per- 
centage of CD4+ T lymphocytes in PBMCs; data were 
expressed as relative copy number of nucleic acid species 
per 10” CD4+ cells and then log transformed. 
Statistical Analysis 
Linear regression analysis was performed to evaluate cor- 
relations between quantitative parameters, and quantita- 
tive variations between baseline and l-year follow-up 
were evaluated using Student’s t-test for dependent vari- 
ables. Changes in values during the study period were 
analyzed by repeated measurement analysis of variance 
(ANOVA), whereas comparison between frequencies of 
qualitative variables was performed using chi-squared 
test. 
RESULTS 
From October 1996 to May 1997, 82 patients were 
enrolled in this study and consecutive blood samples 
were obtained from all subjects. All enrolled patients 
showed good adherence to the therapy; no relevant side 
effects or intolerance to drug regimens were observed, 
and all patients completed the study period. Patients were 
divided in two groups according to CD4 cell count 
obtained at baseline. CD4 cell counts were below 
350/mm3 (mean, 267 ? 65) in 43 (52.4%) and between 
351 and 700/mm3 (mean, 475 + 78) in 39 (47.6%) sub- 
jects. According to the CDC classification system, 70 of 
82 (85.4%) patients were at stage A2,4 of 43 with CD4 
counts below 350/mmj and 8 of 39 with CD4 counts 
between 35 l/mm3 and 700/mm3 were at stage A3 and Al, 
respectively; neither AIDS-defining illness nor clinical pro 
gression of disease was observed during the study. 
At baseline, in the group with CD4 count 350/mm’ 
or less (n = 43) 18 patients (41.9%) had undetectable 
levels of plasma HIV-RNA (~50 copies/ml) and 5 (11.6%) 
and 2 (4.6%) had undetectable levels (~2 copies/lo5 
PBMCs) of proviral DNA and RNA transcripts, respec- 
tively The corresponding figures among the 39 subjects 
with CD4 count between 351/mm3 and 700/mm3 were 
16 (4 1 .O%), 1 (2.6%) and 1 (2.6%), respectively. The mean 
values for each parameter are shown in Table 1. 
In patients with CD4 count of 350/mm” or less, HIV- 
RNA copy number in plasma was correlated with con- 
centrations of proviral DNA and RNA in PBMCs (r = .45, 
P = 0.002; r = .6I, P = 0.00001, respectively). In patients 
with CD4 counts between 351/m& and 700/mm3, HIV- 
RNA copy number in plasma was correlated with con- 
centration of RNA specific transcripts (r = .64, P = 
0.00001) but not with proviral DNA concentration (r = 
.14, P = 0.40). 
Plasma HIV-RNA concentrations were evaluated every 
3 months for 1 year. There were persistent decreases from 
the baseline values in both groups. After 1 year of three- 
drug therapy, in groups with CD4 count 350/mm” or less 
and between 35 l/mm” and 700/mmj, the mean HIV-RNA 
decreases in plasma were 0.75 + 0.87 log (range, -0.48 
to -2.3; P = 0.000001) and 0.77 2 0.89 log (range, -0.60 
to -2.3; P = 0.000004), respectively, and patients with 
undetectable virema were 34 of 43 (79.1%) and 33 of 39 
(86.4%) (cl&squared test with baseline values P = 0.00042 
and P = 0.00007, respectively). 
Among patients with undetectable viremia at base- 
line, 13 of 18 (77.2%) in the group with CD4 count 
350/mm3 or less and 12 of 16 (75%) in the group with 
Table 1. Laboratory Parameters at Baseline and after 1 Year of Hiohlv Active Antiretroviral Theraav 
Patients 
CD4<350/mm3(n =43) 
HIV-RNA in plasma+ 
HIV-DNA in PBMCsf 
HIV-RNAin PBMCs* 
CD4=351-700/mm3(n =39) 
HIV-RNA in plasma+ 
HIV-DNA in PBMCst 
HIV-RNA in PBMCst 
Time of Therapy 
Baseline 1 Year P-value* 
267 + 65 (2OG372) 332.6 k 93.3(198-550) 
2.34 + 0.89 (1.39-3.69) 1.59 t 
2.49 
0.43(1.40-3.18) 
2 0.69 (1.00-3.48) 1.69 + 
2.12 
0.66 (1.00-2.70) 
rC_ 0.72 (1.00-3.48) 1.17 + 
475 
0.66(1.00-2.18) 
? 78 (359-629) 533.9 5 
2.33 
90.0 (395-720) 
t 0.88 (1.39-3.69) 1.56 t 
2.38 0.45 (1 .OO-3.83) 
0.44 (1.4Cb3.25) 
5 1.54 -c 
2.03 0.44 (1.0&3.11) 
0.59 (1.00-2.54) 









Data are mean + SD (range). *By Student’s t-test for dependent variables; ‘log copias/mL; *log copies/lOfl CD4+ T calls. 
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CD4 count between 351/mm3 and 700/mm3 maintained 
plasma RNA levels below 50 copies/ml at each time 
point. 
To evaluate both CD4 counts and proviral DNA and 
RNA specific transcripts copy number in PBMCs during 
1 year of therapy, patients in each group were divided 
into two subgroups according to their HIV-RNA levels in 
plasma: subgroup 1, with HIV-RNA copy numbers below 
50 copies/ml at baseline and at each time point; sub- 
group 2, with detectable viremia at least once during the 
study period. 
In subgroup 2, the mean decrease of HIV-RNA levels 
in plasma was 1.02 +- 0.63 log and 1.06 k 0.62 log in 
patients with CD4 350/mm3 or less and between 
351/mm3 and 700/mm3, respectively (P = 0.0000001 for 
each group). 
The mean CD4+ T-cell counts were 332.6 + 93.3 
and 533 + 90.9 after 1 year of therapy (P = 0.000226 and 
P = 0.11, respectively), and in each group, no significant 
differences in the mean increase of CD4 count were 
observed between the two subgroups (P = 0.11 for 
1350/mm3 CD4 group and P = 0.96 for 351/mm3 to 
700/mm3 CD4 group). 
The changes of proviral DNA concentrations owing 
to treatment are graphically depicted in Figure 1. There 
are persistent decreases from the baseline values in the 
two groups of patients (P c 0.001, for each group). The 
mean decreases in proviral DNA copy number in patients 
of subgroup 1 were 0.67 ‘-t 0.7 and 1.03 t 0.53, respec- 
tively in patients with CD4 count 350/mm3 or less and 
with CD4 count between 351/mm3 and 700/mm3. In each 
group, no significant differences in proviral DNA 
decreases were observed between patients in subgroups 
1 and 2. Proviral DNA was higher in patients of subgroup 
2 than in patients of subgroup 1 both in the group with 
CD4 count of 350/mm3 or less and between 351/mm3 
and 700/mm3 (P = 0.0025 and P = 0.02, respectively). In 
30 
-oCD4.351-700undeteclableviremla 
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Figure 1. Mean change in proviral DNA copy number from baseline Figure 2. Correlations between decreases of US-RNA transcript and 
for patients with undetectable and detectable viremia and CD4 proviral DNA levels in patients with undetectable viremia and CD4 
350/mm3 or less or between 351/mm3 and 700/mm3. 350/mm3 or less or between 351/mm3 and 700/mm3. 
subgroup 1,9 of 13 and 11 of 12 patients with CD4 count 
350/mm3 or less and between 351/mm3 and 700/mm3, 
respectively, had detectable levels of proviral DNA in 
PBMCs at baseline. After 1 year of therapy, the corre- 
sponding figures were 4 of 13 and 4 of 12, respectively 
(chi-squared test with baseline values P = 0.049 and 
P = 0.003, respectively). 
In subgroup 2 of each group, 1 of 30 patients with 
CD4 count 350/mm3 or less and 0 of 27 with CD4 count 
between 351/mm3 and 700/mm3 had undetectable lev- 
els of proviral DNA in PBMCs at baseline. The corre- 
sponding figures were 10 of 30 and 12 of 27 at the end 
of the study period (chi-squared test with baseline val- 
ues P = 0.003 and P = 0.00009, respectively). 
In subgroup 2 no significant correlations were 
observed between decreases of HIV-RNA in plasma and 
proviral DNA in PBMCs (P = 0.60 and P = 0.62 in groups 
with I 350 and 351-700/mm3 CD4, respectively). 
Concentrations of RNA-specific transcripts de- 
creased significantly after 1 year of therapy in patients 
with CD4 counts 350/mm3 or less and those with 
between 351/mm3 and 700/mm3 (P < 0.001 for each 
group) (see Table 1). In each group, a significant 
decrease of RNA transcripts also was observed in 
patients of subgroup 1 (p = 0.0004 for both groups). The 
mean values of RNA-specific transcripts were constantly 
higher in patients of subgroup 2 than in patients of sub- 
group 1, in both groups, CD4 count 350/mm3 or less 
and between 351/mm3 and 700/mm3 (P < 0.001 for each 
group). In subgroup 2 of each group, the decrease of US- 
RNA transcript levels was correlated with that of HIV- 
RNA in plasma (P = 0.00003 for both groups). At 
baseline, in subgroup 1 RNA-specific transcripts had 
detectable levels in 11 of 13 and in 11 of 12 patients 
with CD4 count 350/mm3 or less or between 351/mm3 
and 700/mm3, respectively, and significant correlations 
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Table 2. Relation between HIV-DNA and 
US-RNA Transcript Detection PBMCs after 1 Year 




Tested Positive Negative 
CD4 5 350 cells/mm3 (n = 13) 
DNA positive 4 0 4 
DNA negative 9 0 9 
CD4 351-700 cells/mm” (n = 12) 
DNA positive 4 2 2 
DNA negative 8 0 8 
*Positive or negative by CRT-PCR. US-RNA = unspliced RNA. 
and proviral DNA levels in PBMCs (P = 0.0085 and P = 
0.00024, respectively) (Figure 2). For these patients, the 
relation between HIV-DNA and US transcript detection 
in PBMCs after 1 year of therapy is presented in Table 
2. In the group with CD4 count 350/mm3 or less, provi- 
ral DNA remain detectable in 4 of 13 patients, whereas 
all samples were negative for presence of US-RNA tran- 
scripts. Four of 12 patients with CD4 count between 
35 l/mm3 and 700/mm3 were positive for proviral DNA, 
and two of these also were positive for presence of US- 
RNA transcripts. 
DISCUSSION 
An important goal in the quantification of viral load in 
patients infected with HIV-l is direct measurement of 
the impact of antiviral therapy. Previous studies have 
demonstrated that HIV-l proviral DNA in PBMCs provides 
a direct measurement of the number of infected cells and 
correlates with disease progression.23-25 Furthermore, 
proviral DNA remained detectable in PBMCs of infected 
individuals despite the fact that some, including HAART- 
treated patients, had undetectable plasma RNA levels for 
over 1 year. I”.’ 1.z6 
The present study quantified viral RNA in plasma, 
US-RNA transcripts, and proviral DNA in PBMCs in 82 
HIV-l-infected patients treated with HAART for up to 
1 year. Results confirm previous studies, indicating that 
treatments with potent antiretroviral regimens can pro- 
duce significant reduction of HIV-RNA in plasma. Both in 
patients with CD4 count 350/m& or less and in those 
with CD4 count between 351/mm3 and 700/mm3, a sig- 
nificant decrease of HIV-RNA in plasma and a persistent 
and significant decrease of proviral DNA concentrations 
in PBMCs were noted. At the same time, a parallel increase 
of CD4 T-cell count was observed, although it reached 
statistical significance only in those with CD4 cell counts 
of 350 cells/mm3 or less. When the two groups of patients 
were divided into subgroups according to their HIV-RNA 
levels in plasma, no significant differences in proviral 
DNA decreases were observed between patients with 
undetectable viremia at baseline and at each time point 
and those with low but detectable viremia. In the past 
few years, PBMC proviral DNA quantitation has been used 
to assess the viral load response to therapy with 
immunomodulators and nucleoside compounds. HOW- 
ever, these studies came to different conclusions about 
the efficacy of nucleoside inhibitors in reducing proviral 
DNA copy number in these cells.2T-33 The significant 
decrease of proviral load in PBMCs during HAART 
observed here could be explained by specific inhibition 
of both reverse transcriptase and protease viral functions 
that affect the production of infectious virus. 
The results of the subgroups of patients with un- 
detectable viremia were analyzed in detail. At baseline, 
proviral DNA had detectable levels in the majority of 
patients: 9 of 13 (69%) and 11 of 12 (91%) patients with 
CD4 count 350/mm3 or less and CD4 count between 
35 l/mm3 and 700/mm3, respectively A persistent and sig- 
nificant decrease in proviral DNA copy number was 
observed in these patients. Despite this decrease, at the 
end of the study period proviral DNA still was detectable 
by quantitative PCR in 4 of 13 (31%) and 4 of 12 (33%) 
patients. Results concerning persistence of proviral DNA 
are consistent with recent studies in which a small but 
relatively stable compartment of CD4+ T cells carrying 
replication-competent provirus was detected in aggres- 
sively treated patients by limiting dilution virus culture 
of highly purified resting cells.‘o However, although more 
sensitive and specific than proviral DNA quantitation by 
PCR, the enhanced co-culture method currently is not 
available in routine clinical practice to measure the viral 
reservoir. Although part of proviral DNA detected using 
PCR may consist of unintegrated or defective genomes, 
the circulating PBMCs (and those in lymph nodes) prop- 
agate their defective proviral copies by cell division, a 
process that is not inhibited by antiretroviral therapy. The 
defective genomes are found in a high proportion of 
proviral DNA from PBMCs,“*,j5 but a low ,frequency of 
resting CD4+ T cells harboring replication-competent 
provirus still can be detected.‘O In addition, cells that con- 
tain unintegrated provirus may transform to virus-pro- 
ducing cells when provirus is extended and integrated 
into the cellular genome. 36 This implies that even if 
HAART abolishes or reduces the production of new viral 
particles to undetectable levels, HIV-l infection can be 
monitored as long as proviral DNA remains detectable. 
In patients of subgroups with undetectable viremia, 
levels of US-RNA transcripts in PBMCs decreased signifi- 
cantly after 1 year of therapy, and this reduction was cor- 
related with that of proviral DNA. At the end of the study 
period, RNA transcripts were still detectable in two 
patients. Although quantitative analyses of US-RNA tran- 
scripts in PBMCs have been used to assess viral RNA 
expression levels, 18-20 they can represent either genomic 
or mRNA, and whether this persistence is attributable 
to low viral transcriptional activity or a reduction of 
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packaging (and hence release) of infectious virus could 
not be determined in this study. However, Natarajan and 
colleagues demonstrated that prolonged treatment with 
HAART does not result in total suppression of viral 
replication despite suppression of plasma HIV-RNA to 
undetectable levels3’ 
Results obtained in this work demonstrate that pro- 
viral DNA quantitation in PBMCs meets some require- 
ments for good monitoring of HAART: (1) at baseline it 
is measurable in the majority of patients, including those 
with undetectable RNA in plasma; (2) it permits evalua- 
tion of the number of infected cells that represent an 
important viral reservoir; (3) it allows detection of few 
DNA copies in lo5 PBMCs; and (4) it decreases even in 
patients with persistent suppression of plasma viremia. 
The use of proviral DNA as a surrogate marker of 
HIV infection still is to be established. However, data from 
this study suggest that it could be useful in monitoring 
HIV-infected patients with undetectable viremia, in whom 
persistence of proviral DNA can lead to an intensifica- 
tion of therapy regimen.38 Further evaluation is needed 
to correlate the observed trend of proviral DNA with clin- 
ical endpoints. 
In conclusion, in HAART-treated patients, quantifica- 
tion of proviral DNA in PBMCs could be used to deter- 
mine the number of infected cells and may represent the 
next step to monitor patients with suppression of plasma 
viremia. 
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